Previous 10 | Next 10 |
The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this event. For further details see: Adaptimmune Therapeutics (ADAP) Presents At SITC Virtual Annual Meeting 2020 - Slideshow
Beyond Meat (BYND) -23% on Q3 earnings release.InnSuites Hospitality (IHT) -20%.Jumia Technologies (JMIA) -19% on Q3 earnings release.Aurora Cannabis (ACB) -13%.Applied UV (AUVI) -13%.GasLog Partners (GLOP) -13% on Q3 earnings release.Waitr Holdings (WTRH) -...
- Data support continued development of ADP-A2M4CD8 - - On track to start Phase 2 trial in gastroesophageal cancers in the first half of 2021 - PHILADELPHIA, Pa. and OXFORDSHIRE, UK., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell t...
Image source: The Motley Fool. Adaptimmune Therapeutics PLC (NASDAQ: ADAP) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 p.m. ET Operator Continue reading For further details see: Adaptimmune Therapeutics PLC (ADAP) Q3 2020 Earnings Call Trans...
Adaptimmune Therapeutics plc (ADAP) Q3 2020 Earnings Conference Call November 5, 2020 08:30 AM ET Company Participants Juli Miller - Senior Director, IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer Helen Tayton-Martin - Co-Founder and Chief Business Officer Confer...
Adaptimmune (ADAP): Q3 GAAP EPS of -$0.04 beats by $0.19.Revenue of $1.19M (+395.8% Y/Y) beats by $0.17M.Press Release For further details see: Adaptimmune EPS beats by $0.19, beats on revenue
- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation cohorts of the SURPASS trial to be presented at SITC - - Durability of response data fr...
Gainers: Socket Mobile (SCKT) +95%.Zedge (ZDGE) +42%.Marin Software Incorporated (MRIN) +37%.Dogness (International) (DOGZ) +35%.Strattec Security Corporation (STRT) +27%.Ever-Glory International Group (EVK) +24%.SenesTech (SNES) +18%.Recon Technology (RCON) +16%.Impac Mortgage Holdings ...
PHILADELPHIA and OXFORDSHIRE, U.K., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q3 2020, before the U.S. markets open on Thursday, November 5, 2020. Fo...
Adaptimmune Therapeutics (NASDAQ: ADAP) , a clinical-stage cancer specialist, is having another off day today. Specifically, the biotech's shares are down by 16.8% as of 10:55 a.m. EDT Friday morning. For the week, Adaptimmune's stock is now down by over 20%. What's behind this ...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...